Advertisement

Follow us on Twitter @CD_AACR!

From the Current Issue

  • Research Articles | AuthorChoice
    Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
    Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam and David M. Hyman
    Cancer Discov February 1 2020 10 (2) 198-213; DOI:10.1158/2159-8290.CD-19-0966

    Analysis of a cohort from a phase II clinical trial of the pan-HER inhibitor neratinib revealed that multiple mutations in ERBB2 (encoding HER2) or concurrent mutations in ERBB3 (encoding HER3) may confer de novo or acquired resistance to neratinib.

  • Research Articles
    Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
    Claudia X. Dominguez, Sören Müller, Shilpa Keerthivasan, Hartmut Koeppen, Jeffrey Hung, Sarah Gierke, Beatrice Breart, Oded Foreman, Travis W. Bainbridge, Alessandra Castiglioni, Yasin Senbabaoglu, Zora Modrusan, Yuxin Liang, Melissa R. Junttila, Christiaan Klijn, Richard Bourgon and Shannon J. Turley
    Cancer Discov February 1 2020 10 (2) 232-253; DOI:10.1158/2159-8290.CD-19-0644

    Cancer-associated fibroblasts (CAF) expressing Lrrc15, encoding a conserved transmembrane protein, increased in prevalence as mouse pancreatic cancer tumors progressed, and an LRRC15+ TGFβ CAF signature predicted poorer response to immunotherapy in patients with various cancer types.

  • Research Articles | AuthorChoice
    In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma
    Fei Li, Qingyuan Huang, Troy A. Luster, Hai Hu, Hua Zhang, Wai-Lung Ng, Alireza Khodadadi-Jamayran, Wei Wang, Ting Chen, Jiehui Deng, Michela Ranieri, Zhaoyuan Fang, Val Pyon, Catríona M. Dowling, Ece Bagdatlioglu, Christina Almonte, Kristen Labbe, Heather Silver, Alexandra R. Rabin, Kandarp Jani, Aristotelis Tsirigos, Thales Papagiannakopoulos, Peter S. Hammerman, Vamsidhar Velcheti, Gordon J. Freeman, Jun Qi, George Miller and Kwok-Kin Wong
    Cancer Discov February 1 2020 10 (2) 270-287; DOI:10.1158/2159-8290.CD-19-0780

    Deficiency of Asf1a, encoding a histone chaperone, improved response to immunotherapy with anti–PD-1 in mouse models of Kras-mutant lung adenocarcinoma via an increase in M1-like macrophage polarization and T-cell proliferation.

Recent Reviews

News from Cancer Discovery

OnlineFirst Research Articles & Briefs

Show more
Advertisement

OnlineFirst Research Watch

Show more

 

 

Back to top